Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Leap Therapeutics, Inc.
Deciphera Pharmaceuticals, LLC
University of Manchester
NYU Langone Health
GOG Foundation